Drug intelligence / Profile preview

ADX-OBE1

Development stage: Unknown
Lead developer: ADARx Pharmaceuticals
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

ADX-OBE1 is an investigational small interfering RNA (siRNA) therapeutic developed by ADARx Pharmaceuticals. It is being researched for the treatment of obesity and other metabolic diseases. The drug operates in the field of endocrinology and metabolic disease, but its precise molecular target and mechanism of action have not been publicly disclosed as of June 2025. The compound remains in the discovery phase, with no clinical trial data or regulatory approvals reported yet[1].

Beyond the preview

Go deeper on ADX-OBE1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADX-OBE1.

Explore the full profile